Filtered By:
Cancer: Bone Cancers
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 366 results found since Jan 2013.
ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
Transl Res. 2023 Apr 28:S1931-5244(23)00072-5. doi: 10.1016/j.trsl.2023.04.005. Online ahead of print.ABSTRACTAberrant N6-methyladenosine (m6A) modification of mRNAs contributes significantly to the epigenetic tumorigenesis, however, its precise role and the key targets in osteosarcoma (OS) are not defined. Here we reported that selective METTL3 (methyltransferase like 3) elevation and the consequential increase of m6A modification causally affect OS progression. The fast-growing OS cells displayed preferential upregulation of METTL3 and increased m6A modification. Conversely, m6A inhibition by 3-deazaadenosine, siRNA-medi...
Source: Translational Research : the journal of laboratory and clinical medicine - April 30, 2023 Category: Laboratory Medicine Authors: Xueying An Wenshu Wu Lin Yang Jian Dong Bin Liu Junxia Guo Jianmei Chen Baosheng Guo Wangsen Cao Qing Jiang Source Type: research
TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma
This study explored the role of TRIM4 in OS chemotherapy sensitivity and malignant progression. The expression of TRIM4 in OS tissues and cells was examined by RT-qPCR, immunohistochemical staining, and western blot. Specific siRNA was transfected into U2-OS and SAOS2 cells to target TRIM4. Cell biological behavior was examined by CCK-8, Transwell, and flow cytometry experiments. Cisplatin-resistant SAOS2 (SAOS2-Cis-R) cells were established, and the effect of TRIM4 expression on the cisplatin response of SAOS2 cells was tested. Knockdown of TRIM4 significantly inhibited the proliferation, migration, and invasion of U2-OS ...
Source: Applied Biochemistry and Biotechnology - April 28, 2023 Category: Biochemistry Authors: Yan Li Jie Gao Dong Wang Zijin Liu Huawu Zhang Source Type: research
ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
Aberrant N6-methyladenosine (m6A) modification of mRNAs contributes significantly to the epigenetic tumorigenesis, however, its precise role and the key targets in osteosarcoma (OS) are not defined. Here we reported that selective METTL3 (methyltransferase like 3) elevation and the consequential increase of m6A modification causally affect OS progression. The fast-growing OS cells displayed preferential upregulation of METTL3 and increased m6A modification. Conversely, m6A inhibition by 3-deazaadenosine, siRNA-mediated METTL3 knockdown or a METTL3-selective inhibitor by STM2457 effectively inhibits OS cell growth and induc...
Source: Translational Research - April 28, 2023 Category: Research Authors: Xueying An, Wenshu Wu, Lin Yang, Jian Dong, Bin Liu, Junxia Guo, Jianmei Chen, Baosheng Guo, Wangsen Cao, Qing Jiang Source Type: research
IL-1 β stimulates a novel, IKKα -dependent, NIK -independent activation of non-canonical NFκB signalling
In this study, we examined the activation of non-canonical nuclear factor Kappa B (NFκB) signalling in U2OS cells, a cellular metastatic bone cancer model. Whilst Lymphotoxin α1β2 (LTα1β2) stimulated the expected slow, delayed, sustained activation of serine 866/870 p100 phosphorylation and increased cellular expression of p52 NFκB, we found that canonical agonists, Interleukin-1β (IL-1β) and also Tumour necrosis factor-α (TNFα) generated a rapid transient increase in pp100, which was maximal by 15-30 min. This rapid phosphorylation was also observed in other cells types, such as DU145 and HCAECs suggesting the p...
Source: Cellular Signalling - April 20, 2023 Category: Cytology Authors: Kathryn McIntosh Yousif H Khalaf Rachel Craig Christopher West Ashley McCulloch Ajay Waghmare Christopher Lawson Edmond Y W Chan Simon Mackay Andrew Paul Robin Plevin Source Type: research
Thiram, an inhibitor of 11 ß-hydroxysteroid dehydrogenase type 2, enhances the inhibitory effects of hydrocortisone in the treatment of osteosarcoma through Wnt/β-catenin pathway
CONCLUSIONS: Hydrocortisone inhibits osteosarcoma through the Wnt/β-catenin pathway. Thiram inhibits 11HSD2 enzyme activity, reducing hydrocortisone inactivation and promoting the effect of hydrocortisone through the same pathway.PMID:36978114 | PMC:PMC10045229 | DOI:10.1186/s40360-023-00655-0
Source: BMC Pharmacology and Toxicology - March 28, 2023 Category: Drugs & Pharmacology Authors: You Zhang Nanjing Li He Li Maojia Chen Wei Jiang Wenhao Guo Source Type: research
